China NT Pharma Group Co., Ltd.

As of December 31, 2025, China NT Pharma Group Co., Ltd. carries a market capitalization of 552.88M, placing it among publicly traded companies globally. Its enterprise value stands at 897.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, China NT Pharma Group Co., Ltd. has 674.25M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, China NT Pharma Group Co., Ltd. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, China NT Pharma Group Co., Ltd.'s stock has declined approximately 66.07% over the past 52 weeks. The 50-day moving average sits at 0.38, while the 200-day moving average is 0.60.

As of December 31, 2025, China NT Pharma Group Co., Ltd. holds 8.04M in cash and equivalents against 352.45M in total debt, resulting in a net debt position of 343.78M. Total book value stands at -304.51M, with working capital of -674.12M providing operational flexibility.

China NT Pharma Group Co., Ltd.'s most recent stock split took place on July 18, 2024 with a 10:1 split ratio.